Dror Ortho-Design, Inc.
Dror Ortho-Design, Inc. develops an AI-based orthodontic platform designed to correct smiles with less lifestyle disruption than traditional clear aligners. The company’s core product, ZSmile, uses a single smart aligner and pulsating air while the patient sleeps or stays at home, and it is positioned as a dentist-controlled alternative in the smile-correction market.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueThe ZSmile system and related orthodontic device platform used to move teeth discreetly during sleep or at home.
The earlier Aerodentis solution that remains part of the company’s technology history and product lineage.
Software used to plan, monitor, and support dentist-controlled orthodontic treatment workflows.
Activities tied to FDA clearance, patent protection, and product readiness for market launch.
Customers
The company’s target customers are dental professionals, especially general practice dentists and orthodontists who would prescribe and monitor treatment using the platform. Its end users are patients seeking smile correction with less inconvenience than conventional aligners, but the commercial buyer and treatment decision-maker is the dental professional. The company also competes for adoption against clear aligner alternatives, so customer value depends on clinical utility, convenience, and pricing.
They buy or recommend the platform to expand orthodontic services without relying only on orthodontists.
They use the system for smile correction treatment planning and patient monitoring.
They ultimately choose the treatment because the product promises discreet, lower-disruption smile correction.
They adopt the platform to add orthodontic capability and differentiate their service offering.
Strategy
Management is focused on commercializing ZSmile, protecting the underlying intellectual property, and expanding the addressable practitioner base beyond orthodontists to general dentists. The company is also prioritizing financing because it remains in development stage and needs capital to support product development, regulatory work, and market entry.
The company needs a marketable product to move from development stage to revenue generation.
Selling through general dentists expands the reachable market beyond orthodontists.
Patent and trade secret protection are important to defend the technology against larger competitors.
The company is loss-making and needs capital to continue development and commercialization.
Geography
The company is headquartered in the United States and reports in U.S. dollars, but its operating history includes Israeli roots through Dror Ortho-Design Ltd. The filings do not disclose a country revenue split, which suggests the business is still in development and not yet commercially scaled across geographies. Its near-term geographic exposure is therefore tied more to U.S. regulatory approval and commercialization than to a broad international sales footprint.
Risks
The company is an early-stage medical device business with no current revenue, so its ability to continue as a going concern depends on raising additional capital and successfully commercializing the platform. It also faces execution risk in product development, regulatory compliance, supply chain reliability, and competition from much larger aligner brands and teledentistry alternatives.
- Need for additional financingImpact: CriticalLikelihood: High
The company is not generating revenues and must fund development and operations externally.
Exposure: Going concern and dilution risk
- Failure to achieve market acceptanceImpact: HighLikelihood: High
The platform must convince dentists and patients to switch from established aligner solutions.
Exposure: Commercial launch and adoption
- Competition from established aligner brandsImpact: HighLikelihood: High
Large competitors have stronger channels, brand recognition, and resources.
Exposure - Product development and regulatory executionImpact: HighLikelihood: High
The platform is a Class II medical device and commercialization depends on successful development and compliance.
Exposure - Business disruption and supply chain issuesImpact: MediumLikelihood: High
Delays or shortages could interrupt R&D, manufacturing, and future deliveries.
Exposure
Accounting
Judgemental itemsThis policy keeps development spending in current-period losses rather than capitalizing it.
Impact: Affects operating loss and comparability across periods
The company states it needs additional capital to continue operations.
Impact: Important for liquidity disclosure and investor risk assessment
Management notes that average selling price assumptions could affect deferred revenue once sales begin.
Impact: Could affect timing of revenue recognition and margins
The company discloses no such instruments, simplifying current accounting complexity.
Impact: Limits exposure to fair value and hedge accounting issues
Similar listed companies
Publicly listed companies with a comparable business focus.
Vivos Therapeutics, Inc.
VVOS · Surgical & Medical Instruments & Apparatus
Zimmer Biomet Holdings, Inc
ZBH · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Zimmer Biomet Holdings is a U.S.-based medical technology company focused on orthopedic reconstruction and related surgical care.
Align Technology, Inc
ALGN · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Zepp Health Corp
ZEPP · Electronic Computers
Zepp Health Corp is a U.S.-listed consumer electronics company focused on smart wearables and digital health products.
NeuroOne Medical Technologies Corporation
NMTC · Surgical & Medical Instruments & Apparatus
NeuroOne Medical Technologies develops and commercializes minimally invasive neurosurgical devices for diagnosing and treating brain and pain disorders.
zSpace, Inc.
ZSPC · Services-Prepackaged Software
Last updated: 24/09/2026